Protective Effects Against Blood Cancer
A commonly used and inexpensive diabetes drug, Metformin, may offer more benefits than just controlling blood sugar levels. Recent studies suggest that Metformin could potentially help protect against blood cancer, specifically myeloproliferative neoplasms (MNP), a rare type of cancer that originates in the bone marrow.
Strong Findings from Danish Researchers
Danish scientists discovered that diabetics who were taking Metformin were less likely to develop MNP. The drug's anti-inflammatory properties have previously shown protective effects against various age-related diseases, such as heart disease and cognitive decline.
Potential Reduction in Cancer Risk
Research has indicated that individuals who had been taking Metformin for over five years had a 45% lower chance of developing blood cancer compared to those who had not taken the drug. Previous studies have also suggested that Metformin could reduce the risk of breast, colon, and prostate cancer in diabetic patients.
Observational Study and Future Implications
The latest findings were based on an observational study involving over 3,800 patients with MNP and 19,000 individuals without the condition. While observational studies provide valuable insights, they do not definitively prove cause and effect. Researchers caution that more rigorous trials are needed to confirm the direct impact of Metformin on reducing the risk of blood cancer.
A Historical Perspective
Metformin, derived from the compound guanidine found in Goat's Rue, has been used to treat diabetes since the 1950s. Its affordability and widespread use make it a promising candidate for further exploration in cancer prevention and treatment.
